Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia Harboring KMT2A Rearrangement and Its Prognostic Factors

Bingqian Jiang, Yanmin Zhao, Yi Luo, Jian Yu, Yi Chen, Baodong Ye, Huarui Fu, Xiaoyu Lai, Lizhen Liu, Yishan Ye, Weiyan Zheng, Jie Sun, Jingsong He, Yi Zhao, Guoqing Wei, Zhen Cai, He Huang, Jimin Shi

Blood (2023) 142 (Supplement 1): 2243.

https://doi.org/10.1182/blood-2023-182809

Published: 2023

Journal Articles

A Prospective Phase II Clinical Study of Low-Frequency Daratumumab for the Treatment of Systemic Light Chain Amyloidosis

Donghua He, Xinyi Meng, Jingsong He, Wenjun Wu, Jinuo Wang, Chunting Zhu, Xiaoyan Han, Yi Zhao, Gaofeng Zheng, Yi Li, Xing Guo, Qingxiao Chen, Fangshu Guan, Zhen Cai

Blood (2023) 142 (Supplement 1): 3400.

https://doi.org/10.1182/blood-2023-184689

Published: 2023

Journal Articles

Impact of TP53 Allelic State on Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasm

Blood (2023) 142 (Supplement 1): 2228.

https://doi.org/10.1182/blood-2023-184668

Published: 2023

Journal Articles

Biological and Therapeutic Implications of NPM1 -Mutated AML Receiving Allogeneic Hematopoietic Cell Transplantation

Xiaolin Yuan, Yibo Wu, Xiaoyu Lai, Luxin Yang, Jimin Shi, Lizhen Liu, Jian Yu, Yanmin Zhao, Weiyan Zheng, Wenjun Wu, Yi Zhao, Zhen Cai, He Huang, Yi Luo

Blood (2023) 142 (Supplement 1): 7037.

https://doi.org/10.1182/blood-2023-189289

Published: 2023

Journal Articles

Comparison of Long-Term Outcome between Imatinib and Dasatinib Prophylaxis after Allogeneic Stem Cell Transplantation in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia-a Multi-Center Retrospective Study

Fangshu Guan, Luxin Yang, Panpan Zhu, Xiaoyu Lai, Lizhen Liu, Jimin Shi, Yanmin Zhao, Jian Yu, Huarui Fu, Yi Zhao, Jianping Lan, Yi Chen, Ying Lu, Guifang Ouyang, Yang Xu, Xi Qiu, Zhen Cai, He Huang, Yi Luo

Blood (2023) 142 (Supplement 1): 7056.

https://doi.org/10.1182/blood-2023-184478

Published: 2023

Journal Articles

A Single Center Retrospective Study on the Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Myeloid Neoplasms over 50 Years Old

Meng Liu, Xiaoli Wang, Yi Luo, Yanmin Zhao, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Weiyan Zheng, Jie Sun, Jingsong He, Yi Zhao, Guoqing Wei, Zhen Cai, He Huang, Jimin Shi

Blood (2023) 142 (Supplement 1): 7051.

https://doi.org/10.1182/blood-2023-184513

Published: 2023

Journal Articles

Pre-treatment 18 f-FDG PET/CT for Assessing and Predicting Bone Marrow Involvement in Patients with Newly Diagnosed Peripheral T-Cell Lymphoma

Jing Chen, Zhen Cai, Yi Zhao

Blood (2023) 142 (Supplement 1): 4494.

https://doi.org/10.1182/blood-2023-185427

Published: 2023

Journal Articles

Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma:Pathological Phenotype and Genetic Mutation Analysis of 12 Patients

Linlin Huang, Hanjin Yang, Yang Yang, Fang Yu, Yi Zhao, Xiujin Ye, Weiyan Zheng, Jie Sun, Enfan Zhang, Zhen Cai, Jingsong He

Blood (2023) 142 (Supplement 1): 4448.

https://doi.org/10.1182/blood-2023-186056

Published: 2023

Journal Articles

Real-World Clinical Outcomes of Pomalidomide-Based and Daratumumab-Based Therapies in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Center Retrospective Cohort Study

Xiaoyan Han, Xincheng Jiang, Jingsong He, Gaofeng Zheng, Yaqin Xiong, Yanling Wen, Yang Yang, Donghua He, Qingxiao Chen, Wenjun Wu, Yi Zhao, Yi Li, Zhen Cai

Blood (2023) 142 (Supplement 1): 6639.

https://doi.org/10.1182/blood-2023-184794

Published: 2023

Journal Articles

Hyperleukocytosis Does Not Present a Worse Prognosis in Acute Myeloid Leukemia (Non-APL) with Favorable Risk According to ELN-2022 Criteria: A Retrospective Study

Shuyue Bao, Jinya Lin, Yuanyuan Zhu, Weijia Huang, Weiyan Zheng, Guoqing Wei, Zhen Cai, Yi Luo, Yi Zhao, Jimin Shi, He Huang, Jie Sun

Blood (2023) 142 (Supplement 1): 5867.

https://doi.org/10.1182/blood-2023-186943

Published: 2023

Journal Articles

IPSS-M Predicts Survival Outcomes Significantly Better Than IPSS-R in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasms

Blood (2023) 142 (Supplement 1): 3579.

https://doi.org/10.1182/blood-2023-189068

Published: 2023

Journal Articles

Clinical Characteristics Analysis of Gastrointestinal Peripheral T-Cell Lymphoma:Impact of Non-Emergency Surgery on Overall Survival

Jingsong He, Linlin Huang, Yang Yang, Yi Zhao, Xiu-Jin Ye, Weiyan Zheng, Sun Jie, Zhen Cai

Blood (2023) 142 (Supplement 1): 6214.

https://doi.org/10.1182/blood-2023-185509

Published: 2023

Journal Articles

Preliminary Outcomes of Orelabrutinib Plus R-CHOP in Treatment-Naive Patients with Double-Expression Diffuse Large B-Cell Lymphoma

Yang Yang, Jingsong He, Yi Zhao, Wenjun Wu, Gaofeng Zheng, Xiaoyan Han, Donghua He, Tao Cheng, Zhen Cai

Blood (2023) 142 (Supplement 1): 6222.

https://doi.org/10.1182/blood-2023-187906

Published: 2023

Journal Articles

When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study

Xincheng Jiang, Zhen Cai, Xiaoyan Han, Fengyan Jin, Gang An, Jian Hou, Jingsong He, Qingming Wang, Wenjun Wu, Yi Zhao, Songfu Jiang, Shuchan Li, Zhenshu Xu, Gaofeng Zheng, Yang Yang, Qingxiao Chen, Donghua He, Yi Li

Blood (2023) 142 (Supplement 1): 6673.

https://doi.org/10.1182/blood-2023-174224

Published: 2023

Journal Articles

Preliminary Outcomes of Orelabrutinib Plus RCHOP in Treatment-Naïve Patients with Double-Expression Diffuse Large B Cell Lymphoma

Yang Yang, Jingsong He, Yi Zhao, Wenjun Wu, GaoFeng Zheng, Xiaoyan Han, Donghua He, He Huang, Zhen Cai

Blood (2022) 140 (Supplement 1): 12102–12103.

https://doi.org/10.1182/blood-2022-168017

Published: 2022

Journal Articles

The Efficacy of Residual Plerixafor of Second-Day Stem Cell Mobilization in Multiple Myeloma Patients

Donghua He, Chunting Zhu, Xing Guo, Xin Huang, Xiaoyan Han, GaoFeng Zheng, Yi Zhao, Yang Yang, Wenjun Wu, Jimei Ge, Enfan Zhang, He Huang, Jingsong He, Zhen Cai

Blood (2022) 140 (Supplement 1): 12813–12814.

https://doi.org/10.1182/blood-2022-166394

Published: 2022

Journal Articles

Analysis of Clinical Characteristics and High-Risk Factors of Patients with Extramedullary Relapse Multiple Myeloma

XiaoYan Yue, GaoFeng Zheng, Donghua He, Yang Yang, Xiaoyan Han, Yi LI, Yi Zhao, Qingxiao Chen, WenJun Wu, He Huang, Zhen Cai, Jingsong He

Blood (2022) 140 (Supplement 1): 7197.

https://doi.org/10.1182/blood-2022-159859

Published: 2022

Journal Articles

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Yi Li, Jingsong He, Xiaoyan Han, Gaofeng Zheng, Enfan Zhang, Qingxiao Chen, Donghua He, Yi Zhao, Jiaping Fu, Lihong Shou, Wenhua Jiang, Wei Jiang, Shenxian Qian, Huixian Hu, He Huang, Zhen Cai

Blood (2021) 138 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2021-149188

Published: 2021

Journal Articles

Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-138614

Published: 2020

Journal Articles

Cfi-400945 Induces Cytokinesis Failure By Activating Hippo Signaling Pathway in Diffuse Large B-Cell Lymphoma

Yi Zhao, MM, Juan Yang, PhD, Jiarui Liu, Shuai Ren, MM, Yiqing Cai, Shunfeng Hu, MM, Xiangxiang Zhou, MD, Xin Wang, MDPhD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-141885

Published: 2020

NARROW

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia Harboring KMT2A Rearrangement and Its Prognostic Factors

A Prospective Phase II Clinical Study of Low-Frequency Daratumumab for the Treatment of Systemic Light Chain Amyloidosis

Impact of TP53 Allelic State on Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasm

Biological and Therapeutic Implications of NPM1 -Mutated AML Receiving Allogeneic Hematopoietic Cell Transplantation

Comparison of Long-Term Outcome between Imatinib and Dasatinib Prophylaxis after Allogeneic Stem Cell Transplantation in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia-a Multi-Center Retrospective Study

A Single Center Retrospective Study on the Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Myeloid Neoplasms over 50 Years Old

Pre-treatment 18 f-FDG PET/CT for Assessing and Predicting Bone Marrow Involvement in Patients with Newly Diagnosed Peripheral T-Cell Lymphoma

Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma:Pathological Phenotype and Genetic Mutation Analysis of 12 Patients

Real-World Clinical Outcomes of Pomalidomide-Based and Daratumumab-Based Therapies in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Center Retrospective Cohort Study

Hyperleukocytosis Does Not Present a Worse Prognosis in Acute Myeloid Leukemia (Non-APL) with Favorable Risk According to ELN-2022 Criteria: A Retrospective Study

IPSS-M Predicts Survival Outcomes Significantly Better Than IPSS-R in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasms

Clinical Characteristics Analysis of Gastrointestinal Peripheral T-Cell Lymphoma:Impact of Non-Emergency Surgery on Overall Survival

Preliminary Outcomes of Orelabrutinib Plus R-CHOP in Treatment-Naive Patients with Double-Expression Diffuse Large B-Cell Lymphoma

When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study

Preliminary Outcomes of Orelabrutinib Plus RCHOP in Treatment-Naïve Patients with Double-Expression Diffuse Large B Cell Lymphoma

The Efficacy of Residual Plerixafor of Second-Day Stem Cell Mobilization in Multiple Myeloma Patients

Analysis of Clinical Characteristics and High-Risk Factors of Patients with Extramedullary Relapse Multiple Myeloma

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Cfi-400945 Induces Cytokinesis Failure By Activating Hippo Signaling Pathway in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only